跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Cov-X
首页
药物
Cov-X
Cov-X
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION
EP 4622959 A1
申请人: MERCK SHARP & DOHME LLC
优先权: 2022
CN
EP
US
WO
4 件公开
SALT OF NUCLEOSIDE ANALOG AND CRYSTAL FORM THEREOF, PHARMACEUTICAL COMPOSITION AND USE
EP 4234557 A4
申请人: VIGONVITA LIFE SCIENCES CO LTD
优先权: 2020
CN
EP
WO
3 件公开
ANTI-SARS-COV-2 DRUG
US 20250325547 A1
申请人: UNIV KAGOSHIMA
优先权: 2021
CN
EP
US
3 件公开
PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2
EP 4598914 A1
申请人: TOCRIS COOKSON LTD
优先权: 2022
EP
US
WO
3 件公开
PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION
EP 4649086 A1
申请人: MERCK SHARP & DOHME LLC
优先权: 2023
EP
US
WO
3 件公开
SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUND AS PHARMACEUTICAL FOR TREATMENT OR PREVENTION OF COVID-19
EP 4707279 A1
申请人: ALBIUS SCIENCES BETA PTE LTD
优先权: 2023
CN
EP
WO
3 件公开
CXC CHEMOKINE AGONISTS AND ANTAGONISTS IN COVID-19 DISEASE AND DIAGNOSTIC ASSAYS
US 2024325496 A1
申请人: UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION
优先权: 2021
US
WO
2 件公开
PLPRO INHIBITORS
US 20250059159 A1
申请人: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD
优先权: 2021
CN
US
2 件公开
PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2
EP 4598582 A1
申请人: TOCRIS COOKSON LTD
优先权: 2022
EP
WO
2 件公开
SARS-CoV virus structural protein infusion protein and its high yield expression and purification and uses
CN 1884303 A
申请人: INST BASIC MED SCIENCES PLA
优先权: 2005
CN
第 1 / 3 页
上一页
下一页
药物
反馈